No Data
Olema Oncology to Present New Data Combining Palazestrant With Ribociclib at the San Antonio Breast Cancer Symposium
J.P. Morgan Keeps Their Buy Rating on Olema Pharmaceuticals (OLMA)
Express News | Olema Pharmaceuticals Inc : JP Morgan Cuts Target Price to $29 From $31
A Quick Look at Today's Ratings for Olema Pharmaceuticals(OLMA.US), With a Forecast Between $29 to $30
Optimistic Outlook for Olema Pharmaceuticals: Promising Clinical Data and Strategic Pipeline Developments
TD Cowen Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating
President Sean Bohen Sold A Bunch Of Shares In Olema Pharmaceuticals
